At a glance
ClinicalIndex Comparison RecordEarly Ph 1Not Yet Recruiting· 12 target
Drug / intervention
CMTS0929biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CMTS0929 for Inflammatory Bowel Disease: a Prospective, Open-label, Single-arm Clinical Study
The Second Hospital of Nanjing Medical University·interventional·Posted Feb 25, 2025·Updated Feb 25, 2025
In Brief
A Early Phase 1 clinical trial evaluating CMTS0929 for Inflammatory Bowel Disease (IBD). Not yet recruiting, targeting 12 participants across 1 site.
Detailed Summary
This is a prospective, open-label, single-arm study to explore the safety and the efficacy of China Microbiota Transplantation System 0929 (CMTS0929) for patients with inflammatory bowel disease (IBD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammatory Bowel Disease (IBD)
CountriesChina
Collaborators--
Timeline
Early Ph 1Not Yet Recruiting
202520262027202820292030
Enrollment StartFeb 2025
First PostedFeb 2025
TodayJul 2026
Primary CompletionJan 2030
Study CompletionJul 2030
First PostedFeb 25, 2025
Enrollment StartFeb 20, 2025
Primary CompletionJan 31, 2030
Study CompletionJul 1, 2030
TodayJul 1, 2026
Enrollment to primary: 4.9 yearsPosted 1.3 years agoPrimary completion in 3.6 years
Interventions
CMTS0929biological
China Microbiota Transplantation System 0929 (CMTS0929) is defined as suspension from washed microbiota.